Anticancer drugs: Next in line?

@article{Kirkpatrick2002AnticancerDN,
  title={Anticancer drugs: Next in line?},
  author={Peter Kirkpatrick},
  journal={Nature Reviews Drug Discovery},
  year={2002},
  volume={1},
  pages={566-566}
}
556 | AUGUST 2002 | VOLUME 2 www.nature.com/reviews/cancer The success of the kinase inhibitor imatinib (Glivec) in the treatment of chronic myelogenous leukaemia — which is caused by the aberrant activity of the BCR–ABL tyrosine kinase — has given much encouragement for the development of other molecularly targeted therapies. As two reports in Cancer Cell… CONTINUE READING